Severe acute respiratory syndrome coronavirus 2 · seed P0DTC2 · 1273 aa · family defined as ≥30% identity to that seed · compiled 07 October 2026
Open in CODSWALLOP UniProt P0DTC2 RCSB by accession PDBe-KB AlphaFold DB InterPro CATH 2.60.120.960 CATH 2.60.40.10 SCOP 8037105 SCOP 8092469 SCOP 8092467 SCOP 8092661 SCOP 8092663 SCOP 8092471 SCOP 8092473 RCSB 7EAN PDBe
CATH and SCOP identifiers come from the RCSB's own structure annotations, which the Domains panel already reads, so these are looked up rather than guessed at.
Every figure here is counted over the whole family rather than quoted from one entry.
7EAN, the structure every other member of this family is superposed onto. Rendered by the RCSB and embedded here: the live app shows an interactive viewport, which a document that fetches nothing cannot.
How many of this family's constructs contain each residue of the seed. A trough is a stretch nobody has put in a construct, which is a construct-design answer rather than a disorder one.
821 distinct constructs across 1,991 entries. 1,968 polymer entities differ from the UniProt canonical sequence in some way, 601 carry a recognised expression tag and 5 carry a fusion partner.
"Differs from canonical" is not the same as "engineered". The canonical sequence is the full gene product, so a secreted protein whose structures all start after its signal peptide counts every one of them as different: lysozyme's most-used construct, residues 19–147 on 1,239 entities, is simply the mature protein. Read the construct column below for what was actually done, rather than this count.
| Entities | Length | Best (Å) | Best entry | What was made |
|---|---|---|---|---|
| 56 | 1288 | 2.20 | 7LXY | Strep-II; 1 internal deletion; 3-residue insertion after 1208; R682G, R683S, R685S +41 more |
| 40 | 1288 | 2.62 | 7B18 | Strep-II; 1 internal deletion; 3-residue insertion after 1208; R682G, R683S, R685S +37 more |
| 36 | 205 | 1.71 | 8CWU | residues 333-537; T531G, N532H, L533H +4 more |
| 29 | 1283 | 2.70 | 7CZT | FLAG; K986P, V987P |
| 25 | 223 | 1.91 | 7EAN | residues 319-541 |
| 24 | 205 | 1.85 | 7MZI | residues 331-535; K528G, K529S, S530H +5 more |
| 24 | 231 | 1.71 | 7JMP | residues 319-549; N542S, F543G, N544H +5 more |
| 20 | 195 | 1.75 | 7OLZ | residues 333-527 |
| 17 | 194 | 2.10 | 7Y3O | residues 334-527 |
| 17 | 1256 | 2.80 | 7UAP | 3 internal deletions; 7-residue insertion after 1259; R685A, F817P, A892P +30 more |
| 17 | 1286 | 3.16 | 7TOV | Strep-II; 2 internal deletions; 3-residue insertion after 1208; T19R, G142D, R158G +43 more |
| 16 | 194 | 2.40 | 7X2K | residues 333-526 |
| 16 | 205 | 1.77 | 7NEH | residues 324-528; S325T, I326G, V327H +6 more |
| 16 | 1261 | 2.70 | 7DF3 | FLAG+His9; residues 1-1224; 14-residue insertion after 1208; R682G, R683S, R685S +14 more |
| 15 | 1280 | 2.80 | 7RU1 | residues 1-1267; 1 internal deletion; 14-residue insertion after 1208; R682G, R683S, R685S +43 more |
| 15 | 1288 | 2.80 | 7ND9 | Strep-II; 1 internal deletion; 3-residue insertion after 1208; R682G, R683S, R685S +37 more |
| 15 | 1288 | 3.20 | 7YVK | 1 internal deletion; 14-residue insertion after 1208; T19I, G142D, V213G +83 more |
| 14 | 1208 | 3.10 | 7YC5 | residues 1-1208; R682G, R683S, R685S +6 more |
| 14 | 1258 | 3.30 | 7WD0 | FLAG+His9; residues 1-1224; 1 internal deletion; 14-residue insertion after 1208; L18F, D80A, D215G +23 more |
| 14 | 1273 | 2.30 | 8CXQ | K986P, V987P |
| 13 | 202 | 2.30 | 8QRG | residues 327-528; V327H, R328H, F329H +6 more |
| 13 | 1281 | 2.70 | 7V8A | 1 internal deletion; 6-residue insertion after 1227; T19R, G142D, R158G +64 more |
| 12 | 1234 | 2.10 | 8G71 | residues 14-1241; 6-residue insertion after 1227; D614G, R682A, R683G +31 more |
| 12 | 1278 | 3.10 | 7X8W | 1 internal deletion; 6-residue insertion after 1227; R682G, R683S, R685S +59 more |
| 12 | 1281 | 2.60 | 7K43 | His6; 2 internal deletions; 3-residue insertion after 12; M1S, F2L, V3L +49 more |
Showing the 25 most-used of 821.
Columns where the wild-type residue still dominates but a real minority carries something else, which is a different question from "what varies across species".
| Oligomeric state | Chains | Entries | Share |
|---|---|---|---|
| trimeric | 3 | 843 | 42.3% |
| dimeric | 2 | 308 | 15.5% |
| pentameric | 5 | 211 | 10.6% |
| nonameric | 9 | 201 | 10.1% |
| tetrameric | 4 | 132 | 6.6% |
| hexameric | 6 | 126 | 6.3% |
| heptameric | 7 | 89 | 4.5% |
| pentadecameric | 15 | 20 | 1.0% |
458 entries have the depositor's assembly corroborated by PISA, 1,526 carry the depositor's word alone and 7 were assigned by PISA where the depositor gave none. The middle figure is not a disagreement: PISA may have returned nothing or never run. 4 entries carry more than one assembly with different chain counts, so they have no single answer to quote: 3D0H, 3D0I, 8ELP, 9JTD.
Every source's own domains on the seed axis, one row each. They are not merged: Pfam, CATH, SCOP and InterPro disagree about boundaries, and a merged track would state a consensus none of them gave.
| Domain | Source | Span (seed) | Chains |
|---|---|---|---|
| Spike glycoprotein, N-terminal domain | CATH 2.60.120.960 | 28–317 | 495 |
| Immunoglobulins | CATH 2.60.40.10 | 336–439 | 183 |
| Metalloproteases (zincins), catalytic domain | SCOP2B 8037105 | 15–610 | 31 |
| Concanavalin A-like lectins/glucanases | SCOP2B 8092469 | 27–293 | 612 |
| SARS coronavirus receptor-binding domain-like | SCOP2B 8092467 | 335–526 | 1,275 |
| Coronavirus S1 glycoprotein, domain C-like | SCOP2B 8092661 | 529–592 | 852 |
| Coronavirus S1 glycoprotein, domain D-like | SCOP2B 8092663 | 593–699 | 169 |
| Coronavirus S2 glycoprotein stalk-like | SCOP2B 8092471 | 717–1068 | 850 |
| Coronavirus spike S2 glycoprotein connector domain-like | SCOP2B 8092473 | 1074–1146 | 854 |
| Component | Class | Name | Entries | Best (Å) |
|---|---|---|---|---|
| NAG | cofactor | 2-Acetamido-2-Deoxy-Beta-D-Glucopyranose | 1,401 | 1.21 |
| ZN | ion | Zinc Ion | 158 | 2.08 |
| GOL | cryoprotectant | Glycerol | 91 | 0.96 |
| CL | ion | Chloride Ion | 83 | 1.55 |
| SO4 | ion | Sulfate Ion | 49 | 1.70 |
| EDO | cryoprotectant | 1,2-Ethanediol | 47 | 1.21 |
| EIC | ligand | Linoleic Acid | 26 | 1.88 |
| PEG | cryoprotectant | Di(Hydroxyethyl)ether | 25 | 1.77 |
| PO4 | ion | Phosphate Ion | 17 | 1.94 |
| BLA | ligand | Biliverdine Ix Alpha | 17 | 1.82 |
| CIT | buffer | Citric Acid | 14 | 1.55 |
| ACT | cryoprotectant | Acetate Ion | 11 | 1.21 |
| PG4 | cryoprotectant | Tetraethylene Glycol | 11 | 1.82 |
| NA | ion | Sodium Ion | 11 | 1.55 |
| MAN | cofactor | Alpha-D-Mannopyranose | 10 | 2.36 |
| TRS | buffer | 2-Amino-2-Hydroxymethyl-Propane-1,3-Diol | 10 | 1.67 |
| PGE | cryoprotectant | Triethylene Glycol | 9 | 1.82 |
| MG | ion | Magnesium Ion | 5 | 1.87 |
| NO3 | ion | Nitrate Ion | 5 | 1.59 |
| DMS | cryoprotectant | Dimethyl Sulfoxide | 4 | 2.42 |
Parsed from the free text 545 depositors typed into
_exptl_crystal_grow.pdbx_details, out of 545
entries that recorded anything at all.
Median pH 7.0
(range 3.3 to 10.5).
1,986 entries carry a wwPDB validation report: 1,465 clean, 399 worth a check and 122 with something to explain. Median clashscore 6.02, median RSRZ outliers 3.72%, median R-free minus R-work 0.041. 1,984 have released structure factors.
| Organism | Entries | Best (Å) | Ligand-bound | Seed covered |
|---|---|---|---|---|
| Severe acute respiratory syndrome coronavirus 2 | 1,832 | 0.96 | 1307 | 100% |
| Severe acute respiratory syndrome coronavirus | 32 | 2.40 | 19 | 100% |
| Severe acute respiratory syndrome-related coronavirus | 28 | 2.20 | 14 | 96% |
| Homo sapiens | 18 | 1.90 | 14 | 95% |
| Bat coronavirus RaTG13 | 12 | 2.60 | 11 | 95% |
| Sarbecovirus | 11 | 2.13 | 10 | 95% |
| Bat SARS-like coronavirus WIV1 | 9 | 1.88 | 8 | 95% |
| Pangolin coronavirus | 9 | 2.45 | 6 | 17% |
| Human betacoronavirus 2c EMC/2012 | 5 | 2.80 | 2 | 84% |
| Middle East respiratory syndrome-related coronavirus | 4 | 2.59 | 3 | 83% |
| Saccharomyces cerevisiae S288C | 4 | 2.70 | 4 | 21% |
| Bat SARS-like coronavirus RsSHC014 | 3 | 2.24 | 2 | 95% |
1273 residues, numbered every ten. Every identity figure in this document is measured against this sequence.
active or binding site modified residue or glycosylation disulphide cysteine transmembrane or signal the 15 most-substituted positions
Sites are UniProt's curated features where the seed is a UniProt accession; the substituted positions are measured from this family's own alignment rather than annotated, and only the fifteen most substituted are marked: every position carrying a minority substitution would be most of the protein, because the family holds orthologues. A residue can carry more than one and is drawn with the first that applies, in the order of the key above.
One record per paper, not per entry.
| Year | Citation |
|---|---|
| 2026 | Monoclonal antibodies from COVID-19 convalescent patients target cryptic epitopes for broad SARS-CoV-2 neutralization. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2523864123 |
| 2026 | Mining antibody functionality via AI-guided structural landscape profiling. Nat Commun doi:10.1038/s41467-026-70553-6 |
| 2026 | Modification of a SARS-CoV-2 spike-RBD targeting nanobody for pH-dependent binding and its chromatographic engineering for purification of WT and variant S-RBDs with mild elution conditions. Int.J.Biol.Macromol. doi:10.1016/j.ijbiomac.2025.149749 |
| 2026 | IgG-Bridging-Seeded Synergistic Aggregation of SARS-CoV-2 Spikes Underlies Potent Neutralization by a Low-Affinity Antibody. Adv Sci doi:10.1002/advs.202517192 |
| 2026 | A structural and mechanistic atlas of NTD antibody neutralization and immune escape across SARS-CoV-2 prototype and its (sub-)variants. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2535385123 |
| 2026 | In vivo evolution of antibody CR3022 expands cross-neutralization of SARS-CoV-2 variants and informs pan-sarbecovirus immunity. Cell Rep doi:10.1016/j.celrep.2026.117137 |
| 2026 | Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS-CoV-2 Omicron Variants. Adv Sci doi:10.1002/advs.76522 |
| 2026 | mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2536870123 |
| 2026 | Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants. Nat Microbiol doi:10.1038/s41564-026-02282-x |
| 2026 | TMPRSS2-mediated coronavirus spike activation and inhibition. Nat.Struct.Mol.Biol. doi:10.1038/s41594-026-01801-y |
| 2026 | Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants. Nat Commun doi:10.1038/s41467-026-68462-9 |
| 2026 | Defining the mechanism of cross-reactivity for a SARS-CoV-2 Beta-elicited antibody toward omicron sub-lineages. Structure doi:10.1016/j.str.2026.01.006 |
| 2026 | The buried S2 apex of SARS-CoV-2 spike elicits an immunodominant germline-restricted public antibody response. Biorxiv doi:10.64898/2026.02.18.706653 |
| 2026 | Virological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia. Cell doi:10.1016/j.cell.2026.04.019 |
| 2026 | Twenty-year persistence of SARS-CoV-1 immune imprinting shapes antibody responses to SARS-CoV-2 infection. Immunity doi:10.1016/j.immuni.2026.08.009 |
| 2026 | Enteric alpha-defensins contribute to intestinal mucosal immunity against SARS-CoV-2 infection. Mucosal Immunol doi:10.1016/j.mucimm.2026.100392 |
| 2026 | Broad Neutralizing Activity of Monoclonal Antibodies Against the Omicron Variants Isolated From Patients With Early Severe Acute Respiratory Syndrome Coronavirus-2. J Med Virol doi:10.1002/jmv.70969 |
| 2026 | Mass spectrometry-based mapping of conformational epitopes on SARS-CoV-2 antigens targeted by monoclonal antibodies. Int.J.Biol.Macromol. doi:10.1016/j.ijbiomac.2026.153102 |
| 2026 | Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit. Plos Pathog. doi:10.1371/journal.ppat.1014391 |
| 2026 | Biophysical trade-offs in antibody evolution are resolved by conformation-mediated epistasis. Biorxiv doi:10.64898/2026.03.12.711465 |
| 2026 | The computationally designed TRI2-2 miniprotein inhibitor protects against multiple SARS-CoV-2 Omicron variants. Commun Biol doi:10.1038/s42003-025-09499-2 |
| 2026 | Species- and variant-specific ACE2 compatibility shapes SARS-CoV-2 spillover potential in North American cervids. Nat Commun doi:10.1038/s41467-026-71623-5 |
| 2026 | Cryo-EM structure of locked spike glycoprotein from bat SARS-like coronavirus WIV1, molecular dynamics and biophysics across host range. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2516874123 |
| 2026 | Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V H 1-2-rearranging mouse models. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2537053123 |
| 2026 | Neutralization of SARS-CoV-2 by IgM-14 via engagement of two distinct spike epitopes. Plos Pathog. doi:10.1371/journal.ppat.1014071 |
| 2026 | Molecular basis of fox ACE2 recognition by receptor binding domains of SARS-CoV-2 and PCoV-GD. Cell Insight doi:10.1016/j.cellin.2026.100314 |
| 2026 | Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants. Res Sq doi:10.21203/rs.3.rs-9917568/v1 |
| 2026 | Public antibody clonotypes and deep learning identify SARS-CoV-2 and HIV broadly neutralizing antibodies in immune repertoires. Cell Rep doi:10.1016/j.celrep.2026.117582 |
| 2026 | Steric hindrance of antibody binding in an Omicron spike fusion intermediate. Nature doi:10.1038/s41586-026-10462-2 |
| 2026 | Development of a Thermostable and Broadly Neutralizing Pan-Sarbecovirus Vaccine Candidate. Acs Infect Dis. doi:10.1021/acsinfecdis.5c00479 |
| 2025 | Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants. Mabs doi:10.1080/19420862.2025.2499595 |
| 2025 | Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activity. Int.J.Biol.Macromol. doi:10.1016/j.ijbiomac.2025.145386 |
| 2025 | Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2413465122 |
| 2025 | Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift Cell Rep doi:10.1016/j.celrep.2025.115948 |
| 2025 | Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2417544121 |
| 2025 | Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells. Nat.Biotechnol. doi:10.1038/s41587-024-02346-5 |
| 2025 | Production and cryo-electron microscopy structure of an internally tagged SARS-CoV-2 spike ecto-domain construct. J Struct Biol X doi:10.1016/j.yjsbx.2025.100123 |
| 2025 | Engineering a multivalent antibody nanoparticle to overcome SARS-CoV-2 Omicron immune evasion. Plos Pathog. doi:10.1371/journal.ppat.1013744 |
| 2025 | Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis. Lancet Microbe doi:10.1016/j.lanmic.2025.101103 |
| 2025 | Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2501637122 |